Literature DB >> 4019797

Changes in circulating immune complex concentrations and antibody titres during treatment of Q fever endocarditis.

P V Coyle, J Thompson, A A Adgey, D A Rutter, A Fay, T A McNeill, J H Connolly.   

Abstract

Serum samples from 20 patients with Q fever endocarditis were tested for the presence of circulating immune complexes to see whether their concentrations correlated with antibody titres during treatment and whether they could be used to monitor the response to antimicrobial treatment. Circulating immune complexes were found in all 20 patients. The concentrations in 15 patients correlated with either or both of the Q fever phase 1 and phase 2 antibody titres obtained during treatment. In the other five patients no correlation with the antibody titres was found. There was no association between circulating immune complex concentrations and clinical response to treatment.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4019797      PMCID： PMC499296          DOI： 10.1136/jcp.38.7.743

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


  9 in total

1.  Immune complex assays and stored normal human sera.

Authors:  I Julkunen; P Lindström; O Wager; K Penttinen
Journal:  J Immunol Methods       Date:  1983-01-28       Impact factor: 2.303

2.  The Raji cell radioimmune assay for detecting immune complexes in human sera.

Authors:  A N Theofilopoulos; C B Wilson; F J Dixon
Journal:  J Clin Invest       Date:  1976-01       Impact factor: 14.808

3.  Q-fever endocarditis in England and Wales, 1975-81.

Authors:  S R Palmer; S E Young
Journal:  Lancet       Date:  1982-12-25       Impact factor: 79.321

4.  The clinical implications and the pathogenetic significance of circulating immune complexes in infective endocarditis.

Authors:  R H Kauffmann; J Thompson; R M Valentijn; M R Daha; L A Van Es
Journal:  Am J Med       Date:  1981-07       Impact factor: 4.965

5.  Circulating immune complexes and severe sepsis: duration of infection as the main determinant.

Authors:  M A Pocidalo; C Gibert; P Verroust; M Geniteau; C Adam; Y Madec; C Gaudebout; L Morel-Maroger
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

6.  Serological evaluation of O fever in humans: enhanced phase I titers of immunoglobulins G and A are diagnostic for Q fever endocarditis.

Authors:  M G Peacock; R N Philip; J C Williams; R S Faulkner
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

7.  Circulating immune complexes in infective endocarditis.

Authors:  A S Bayer; A N Theofilopoulos; R Eisenberg; F J Dixon; L B Guze
Journal:  N Engl J Med       Date:  1976-12-30       Impact factor: 91.245

8.  Chronic Q fever endocarditis.

Authors:  M P Varma; A A Adgey; J H Connolly
Journal:  Br Heart J       Date:  1980-06

9.  Q fever in Finland: clinical, immunological and epidemiological findings.

Authors:  J Lumio; K Penttinen; T Pettersson
Journal:  Scand J Infect Dis       Date:  1981
  9 in total
  5 in total

1.  Q-fever and autoimmunity.

Authors:  P Levy; D Raoult; J J Razongles
Journal:  Eur J Epidemiol       Date:  1989-12       Impact factor: 8.082

2.  Long term vascular complications of Coxiella burnetii infection in Switzerland: cohort study.

Authors:  P Y Lovey; A Morabia; D Bleed; O Péter; G Dupuis; J Petite
Journal:  BMJ       Date:  1999-07-31

Review 3.  Endocarditis due to rare and fastidious bacteria.

Authors:  P Brouqui; D Raoult
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

4.  Increases in the levels of Coxiella burnetii-specific immunoglobulin G1 and G3 antibodies in acute Q fever and chronic Q fever.

Authors:  C Capo; I Iorgulescu; M Mutillod; J L Mege; D Raoult
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

5.  Coxiella burnetii Endocarditis in a Patient with Systemic Lupus Erythematosus: A Case Report of a Diagnostic Challenge.

Authors:  Ahmed Alqallaf; Abdulmohsen Alhashim; Mohammad Alajmi; Ameerah Alsaqobi; Wasl Al-Adsani
Journal:  Am J Case Rep       Date:  2020-12-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.